JP2019503172A5 - - Google Patents

Download PDF

Info

Publication number
JP2019503172A5
JP2019503172A5 JP2018533745A JP2018533745A JP2019503172A5 JP 2019503172 A5 JP2019503172 A5 JP 2019503172A5 JP 2018533745 A JP2018533745 A JP 2018533745A JP 2018533745 A JP2018533745 A JP 2018533745A JP 2019503172 A5 JP2019503172 A5 JP 2019503172A5
Authority
JP
Japan
Prior art keywords
domain
amino acid
antibody
residue
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018533745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503172A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/068808 external-priority patent/WO2017117179A1/en
Publication of JP2019503172A publication Critical patent/JP2019503172A/ja
Publication of JP2019503172A5 publication Critical patent/JP2019503172A5/ja
Priority to JP2021087487A priority Critical patent/JP2021119793A/ja
Pending legal-status Critical Current

Links

JP2018533745A 2015-12-28 2016-12-28 定常領域の変異を有する二重特異性抗体およびその使用 Pending JP2019503172A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021087487A JP2021119793A (ja) 2015-12-28 2021-05-25 定常領域の変異を有する二重特異性抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562271844P 2015-12-28 2015-12-28
US62/271,844 2015-12-28
PCT/US2016/068808 WO2017117179A1 (en) 2015-12-28 2016-12-28 Bispecific antibodies having constant region mutations and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021087487A Division JP2021119793A (ja) 2015-12-28 2021-05-25 定常領域の変異を有する二重特異性抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2019503172A JP2019503172A (ja) 2019-02-07
JP2019503172A5 true JP2019503172A5 (cg-RX-API-DMAC7.html) 2020-02-13

Family

ID=57822093

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018533745A Pending JP2019503172A (ja) 2015-12-28 2016-12-28 定常領域の変異を有する二重特異性抗体およびその使用
JP2021087487A Pending JP2021119793A (ja) 2015-12-28 2021-05-25 定常領域の変異を有する二重特異性抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021087487A Pending JP2021119793A (ja) 2015-12-28 2021-05-25 定常領域の変異を有する二重特異性抗体およびその使用

Country Status (7)

Country Link
US (1) US11459405B2 (cg-RX-API-DMAC7.html)
EP (1) EP3397646A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019503172A (cg-RX-API-DMAC7.html)
CN (1) CN108779182A (cg-RX-API-DMAC7.html)
AU (1) AU2016381605A1 (cg-RX-API-DMAC7.html)
CA (1) CA3010027A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017117179A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
KR102545617B1 (ko) 2012-11-28 2023-06-20 자임워크스 비씨 인코포레이티드 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
PL3359576T3 (pl) 2015-10-08 2025-04-14 Zymeworks Bc Inc. Konstrukty polipeptydowe wiążące antygen zawierające łańcuchy lekkie kappa i lambda oraz ich zastosowania
EP3504234A4 (en) 2016-09-29 2020-12-02 Beijing Hanmi Pharmaceutical Co., Ltd. CONSTRUCTIONS OF HETERODIMERIC IMMUNOGLOBULINS AND THEIR PREPARATION PROCESSES
SG10201913260VA (en) 2016-11-18 2020-03-30 Beijing Hanmi Pharmaceutical Co Ltd Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
BR112020009414A2 (pt) * 2018-01-15 2020-11-03 I-Mab Biopharma Us Limited anticorpo, composição, e, célula isolada.
WO2019153200A1 (zh) * 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
JP2021512624A (ja) * 2018-02-11 2021-05-20 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドBeijing Hanmi Pharmaceutical Co., Ltd. 抗pd−1/抗vegf天然抗体構造様ヘテロ二量体型二重特異性抗体及びその製造
WO2019211472A1 (en) * 2018-05-03 2019-11-07 Genmab B.V. Antibody variant combinations and uses thereof
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
WO2020109627A1 (en) * 2018-11-30 2020-06-04 Institut Gustave Roussy Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
CN110272495A (zh) * 2019-06-11 2019-09-24 南京华岩生物技术有限公司 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途
CN114450297A (zh) * 2019-07-12 2022-05-06 普罗维瓦疗法香港有限公司 Il-2组合物及其使用方法
CA3167317C (en) * 2020-02-12 2025-05-27 Eli Lilly And Company CRYSTALLIZATION OF ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS
AU2021278935A1 (en) 2020-05-26 2022-12-08 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
WO2009131239A1 (ja) 2008-04-25 2009-10-29 Kyowa Hakko Kirin Co Ltd 安定な多価抗体
AU2012235758B2 (en) * 2011-03-25 2015-05-07 IGI Therapeutics SA Hetero-dimeric immunoglobulins
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
CN109111524B (zh) * 2011-10-31 2022-10-28 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR102545617B1 (ko) 2012-11-28 2023-06-20 자임워크스 비씨 인코포레이티드 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
US10047163B2 (en) * 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
CN105764922B (zh) * 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP6868394B2 (ja) 2014-05-16 2021-05-12 ファイザー・インク 二重特異性抗体
BR112016027888A2 (pt) * 2014-05-28 2017-10-24 Zymeworks Inc construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado
AU2018281045A1 (en) * 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations

Similar Documents

Publication Publication Date Title
US20240158513A1 (en) FC Variants and Methods for Their Production
JP6161540B2 (ja) Fc変異体及びそれらの生産方法
RU2573915C2 (ru) Содержащие суперспираль и/или привязку белковые комплексы и их применение
US11459405B2 (en) Bispecific antibodies having constant region mutations and uses therefor
JP6048972B2 (ja) ヘテロ多量体タンパク質の産生
JP2019503172A5 (cg-RX-API-DMAC7.html)
JP7253518B2 (ja) 哺乳動物細胞を用いたヘテロ多量体タンパク質の生成